Allogene Therapeutics Announces Participation in November Investor Conferences
30 Ottobre 2023 - 1:30PM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer, today announced that it will
participate in two upcoming investor conferences in November.
TD Cowen’s 7th Annual Fall Oncology Innovation SummitFriday,
November 3, 20238:30AM PT/11:30AM ET
Jefferies London Healthcare ConferenceNovember 15, 20234:30AM
PT/7:30AM ET/1:30PM GMT
Any available webcasts will be posted to the Company's website
at www.allogene.com under the Investors tab in the News and
Events section. Following a live webcast, a replay will be
available on the Company's website for approximately 30 days.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T product candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and at greater
scale to more patients. For more information, please visit
www.allogene.com, and follow @AllogeneTx on X (formerly Twitter)
and LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should,” “designed to” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Forward-looking statements include statements regarding
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: Allogene’s ability to
deliver readily available off-the-shelf cell therapy on-demand,
more reliably, and at greater scale to more patients; and the
therapeutic effects of Allogene’s product candidates including
their ability to treat cancers at various stages. Various factors
may cause material differences between Allogene’s expectations and
actual results, including risks and uncertainties related to: our
product candidates are based on novel technologies, which makes it
difficult to predict the time and cost of product candidate
development and the likelihood of obtaining regulatory approval;
the FDA may disagree with our regulatory plan and we may fail to
obtain regulatory approval of our CAR T cell product candidates;
and our clinical trials may fail to demonstrate the safety and
efficacy of any of our product candidates, which would prevent or
delay regulatory approval and commercialization. These and other
risks are discussed in greater detail in Allogene’s filings with
the SEC, including without limitation under the “Risk Factor”
Heading in its Form 10-Q filed for the quarter ended June 30, 2023.
Any forward-looking statements that are made in this press release
speak only as of the date of this press release. Allogene assumes
no obligation to update the forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Corporate Affairs & Brand Strategy
OfficerChristine.Cassiano@allogene.com
Grafico Azioni Allogene Therapeutics (NASDAQ:ALLO)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Allogene Therapeutics (NASDAQ:ALLO)
Storico
Da Mag 2023 a Mag 2024